Antihypertensive Drugs Market is Estimated to Rise at a CAGR of 3% during the Forecast Period, observes TMR Study

News provided by

Jun 15, 2022, 07:30 ET

The global antihypertensive drugs market is likely to be driven by the introduction of novel drug/therapeutic compounds with disease-modifying capabilities and better effectiveness
North America's considerable market share is due to high uptake of antihypertensive medications in the US and an increasing number of new drug approvals by the US FDA

ALBANY, N.Y., June 15, 2022 /PRNewswire/ -- The revenue of antihypertensive drugs market stood at US$ 30.2 Bn in 2021. The global market is likely to develop at a CAGR of 3% during the forecast period, from 2022 to 2031. The global antihypertensive drugs market is likely to attain a valuation of US$ 40 Bn by 2031. The global antihypertensive drugs market is anticipated to be propelled by a rise in the launch of novel pharmaceuticals and diagnostic agents. Besides, major industrial advancements such as partnerships and set-up of R&D facilities are also expected to fuel antihypertensive drugs market expansion. The global market is expected to be driven by rising disposable income as well as the introduction of innovative disease-modifying treatments during the forecast period. Firms in the antihypertensive drugs industry are projected to benefit from significant expansion in telemedicine and e-Health applications in the long run.

In order to meet treatment objectives, most hypertension patients need a mix of antihypertensive medications. In an effort to boost efficacy of the first drug, combination therapy involves adding some other family of blood pressure medication to it. There is a significant unmet need for antihypertensive medications, indicating a shortage of viable products. This creates a huge opportunity for new market entrants to profit from unmet demands, owing to patient non-compliance or poor compliance with already existing medicines.

Antihypertensive drug trends in stroke patients could reveal critical insights into secondary prevention gaps that are likely to help guide future treatments. In order to acquire a competitive advantage over other market participants, healthcare businesses are strengthening R&D in the fields of resistant hypertension therapy and genomics.

Request Brochure of Antihypertensive Drugs Market Research Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7718

Key Findings of Market Report

Innovative antihypertensive medications and pharmacological treatments, which successfully target illness progression, are predicted to have promising benefits. Novel medicines for disorders such as calcium channel blockers (CCB), angiotensin converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs) are projected to transform the existing picture in the global antihypertensive pharmaceuticals market.
The market is projected to be driven by the introduction of new products that are more safe and more efficient. A few of such medications under development are diuretic azilsartan/amlodipine/hydrochlorothiazide (phase III) by Takeda Pharmaceuticals and fimasartan/amlodipine (phase III) by Boryung Pharmaceutical.
The primary hypertension category is expected to lead the global market in the forthcoming years. Over the last decade, hypertension has gradually become a major public health issue. Salt consumption among children in developed countries is often higher than the recommended amount. In developing countries, a similar tendency prevails, which is likely to act as the largest opportunity for antihypertensive drugs. In the initial years of life, a positive sodium balance is required for development. Nevertheless, excessive salt consumption might have negative cardiovascular implications, which is expected to result in driving market demand for antihypertensive drugs

Request for Analysis of COVID-19 Impact on Antihypertensive Drugs Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=7718

Global Antihypertensive Drugs Market: Growth Drivers

Based on medication, the combination therapy category is expected to lead the market with a significant percentage in terms of revenue. This is one of the key market segments in antihypertensive drugs. This segment is being driven by an increase in the geriatric population suffering from comorbid illnesses like congenital heart disease and an emphasis on combination medications. As a result, companies are ramping up the manufacturing of combination antihypertensive medications to suit the demands of senior individuals with many medical conditions.
In 2021, the hospital pharmacies category led the global market by distribution channel. Hospital pharmacies often have a wide selection of pharmaceuticals on reserve, including specialist and experimental drugs. In order to diversify their revenue streams, hospital pharmacists are extending the supply of hypertension management devices.

Get Exclusive PDF Sample Copy of Antihypertensive Drugs Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7718

Global Antihypertensive Drugs Market: Key Players

Some of the key market players are

Pfizer, Inc.
Takeda Pharmaceutical Company Limited
Boehringer Ingelheim GmbH
Daiichi Sankyo Company, Limited
F. Hoffmann-La Roche Ltd.
Sanofi S.A.

Make an Enquiry Before Buying – https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=7718

Global Antihypertensive Drugs Market: Segmentation

Therapy Type

Diuretics
Angiotensin Converting Enzyme Inhibitors
Angiotensin Receptor Blockers
Beta-blockers
Vasodilators
Calcium Channel Blockers
Renin Inhibitors
Alpha-blockers
Others

Type

Primary Hypertension
Secondary Hypertension

Medication Type

Monotherapy
Combination Therapy
Fixed Dose Combinations

Distribution Channel

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Others

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Healthcare Industry Reports by Transparency Market Research:

Erectile Dysfunction Drugs Market: Increase in use of such drugs to treat the above mentioned disease conditions will continue to encourage the use of erectile dysfunction drugs, thereby driving the erectile dysfunction drugs market.

Point-of-Care Diagnostics Market: Increase in incidence of diabetes, cancer, and other chronic diseases, and technological advancements in the field of point-of-care that has resulted in new and innovative products are projected to drive the global point-of-care diagnostics market during the forecast period.

Rapid Medical Diagnostic Kits Market: Widespread availability, aging population, and shift in technological & commercial environment are projected to drive the global rapid medical diagnostics kits market during the forecast period.

In Vitro Diagnostics Market: Rise in health care expenditure due to increase in awareness about various health care programs and availability of cost-effective diagnostic methods are likely to augment the global in vitro diagnostics market.

Pressure Ulcer Diagnostics Market: Rise in awareness about pressure ulcer diagnostic tools & tests, and surge in COVID-19 patients suffering from pressure ulcers & other chronic diseases are anticipated to boost the growth of the global pressure ulcer diagnostics market during the forecast period.

Lyme Disease Diagnostics Market: The surge in the frequency and prevalence of Lyme disease and rising investments from government organizations and large corporates for developing diagnostic kits are primary reasons contributing to the growth of the global Lyme disease diagnostics market.

Hemostasis Diagnostics Market: Rise in prevalence of blood clotting disorders, high prevalence of cardiovascular diseases are projected to drive the global hemostasis diagnostics market during the forecast period.

Meningitis Diagnostic Testing Market: The EMEA meningitis diagnostic testing market is expected to reach the value of US$ 83.51 Mn by the end of 2031 and to expand at a CAGR of 3.7% from 2021 to 2031. Rapid diagnostic tests are significantly changing the EMEA meningitis diagnostic testing market.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact Us:
Rohit Bhisey Transparency Market Research Inc.
Corporate Headquarter Downtown
1000 N. West Street
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: http://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: [email protected]